Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Apr 14, 2020 (6 years ago)

Finasteride Plus 1.25 mg Capsule

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Cross Contamination with Other Products; Finasteride Plus 1.25mg capsules were found to contain minoxidil.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Finasteride Plus 1.25 mg Capsule, a) 30-count bottle, b) 90-count bottle, Compounded Product Not for Resale, MasterPharm, 115-02 Liberty Ave, Richmond Hill, NY 11419.

Drug: Finasteride

Recalling firm
MasterPharm LLC
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1269-2020 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Finasteride recalls

See all
Class II · Moderate risk

Finasteride Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-6976-3 D-0516-2023
Class II · Moderate risk

Finasteride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0733-90 D-0477-2023
Class II · Moderate risk

Finasteride Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-090-10 D-0392-2023
Class II · Moderate risk

Finasteride Tablets USP 1 mg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 71713-096-90 D-0391-2023

Other recalls by MasterPharm LLC

All 2020 recalls
Class II · Moderate risk

Vardenafil 20 mg Troche

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1442-2020
Class II · Moderate risk

Tadalafil 7 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1440-2020